376.80
0.74%
2.78
Pre-market:
376.00
-0.80
-0.21%
United Therapeutics Corp stock is traded at $376.80, with a volume of 320.80K.
It is up +0.74% in the last 24 hours and up +5.86% over the past month.
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
See More
Previous Close:
$374.02
Open:
$373.98
24h Volume:
320.80K
Relative Volume:
0.85
Market Cap:
$16.82B
Revenue:
$2.62B
Net Income/Loss:
$1.07B
P/E Ratio:
20.76
EPS:
18.15
Net Cash Flow:
$877.90M
1W Performance:
+7.75%
1M Performance:
+5.86%
6M Performance:
+43.60%
1Y Performance:
+67.89%
United Therapeutics Corp Stock (UTHR) Company Profile
Name
United Therapeutics Corp
Sector
Industry
Phone
(301) 608-9292
Address
1000 SPRING ST, SILVER SPRING, MD
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-11-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Feb-12-24 | Upgrade | Goldman | Sell → Neutral |
Feb-05-24 | Initiated | Leerink Partners | Outperform |
Dec-08-23 | Initiated | Wells Fargo | Overweight |
Dec-06-22 | Initiated | UBS | Buy |
Dec-05-22 | Initiated | Goldman | Sell |
Oct-11-22 | Initiated | Morgan Stanley | Overweight |
Sep-20-22 | Reiterated | BofA Securities | Underperform |
Sep-19-22 | Resumed | Wedbush | Outperform |
Feb-11-22 | Initiated | BTIG Research | Neutral |
Jul-14-21 | Upgrade | Argus | Hold → Buy |
Apr-26-21 | Resumed | Credit Suisse | Outperform |
Feb-01-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
Sep-14-20 | Resumed | JP Morgan | Overweight |
Jun-25-20 | Reiterated | H.C. Wainwright | Neutral |
Mar-10-20 | Upgrade | Jefferies | Hold → Buy |
Feb-27-20 | Upgrade | Cowen | Market Perform → Outperform |
Jan-31-20 | Upgrade | JP Morgan | Neutral → Overweight |
Dec-03-19 | Initiated | BofA/Merrill | Underperform |
Aug-01-19 | Upgrade | Jefferies | Underperform → Hold |
Aug-01-19 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
Jul-01-19 | Upgrade | Credit Suisse | Neutral → Outperform |
May-17-19 | Upgrade | UBS | Sell → Neutral |
May-09-19 | Upgrade | Credit Suisse | Underperform → Neutral |
Oct-12-18 | Upgrade | Standpoint Research | Hold → Buy |
Aug-08-18 | Downgrade | Credit Suisse | Neutral → Underperform |
Apr-03-18 | Upgrade | Credit Suisse | Underperform → Neutral |
Feb-22-18 | Reiterated | Barclays | Underweight |
Jan-18-18 | Resumed | Credit Suisse | Underperform |
Dec-27-17 | Reiterated | Wedbush | Outperform |
Apr-27-17 | Reiterated | Wedbush | Outperform |
Mar-30-17 | Initiated | UBS | Sell |
Mar-16-17 | Initiated | Credit Suisse | Underperform |
View All
United Therapeutics Corp Stock (UTHR) Latest News
Insider Sale: Director Christopher Causey Sells Shares of United Therapeutics Corp (UTHR) - GuruFocus.com
United Therapeutics Co. (NASDAQ:UTHR) Director Sells $192,081.30 in Stock - MarketBeat
Sandoz Wins $70M In Antitrust Suit Over Hypertension Drug - Law360
Sandoz's Award Cut to $71 Million in Generic-Remodulin UTC Case - Bloomberg Law
United Therapeutics Corporation (NASDAQ:UTHR) Q3 2024 Earnings Call Transcript - Insider Monkey
New York State Teachers Retirement System Boosts Holdings in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
MannKind Shares Soar to Over 8-Year Highs on United Therapeutics’ Tyvaso Revenue Surge: Retail Is Optimistic - MSN
United Therapeutics (NASDAQ:UTHR) Price Target Raised to $302.00 at The Goldman Sachs Group - MarketBeat
United Therapeutics Q3 Earnings & Sales Beat Estimates - MSN
United Therapeutics (NASDAQ:UTHR) Hits New 52-Week High on Analyst Upgrade - MarketBeat
United Therapeutics stock soars to all-time high of $377.93 - Investing.com
United Therapeutics shares rated Neutral by Ladenburg, target lifted on Tyvaso sales strength - Investing.com Australia
United Therapeutics shares target raised to $425 by H.C. Wainwright - Investing.com India
United Therapeutics Co. (NASDAQ:UTHR) Shares Purchased by AustralianSuper Pty Ltd - MarketBeat
United Therapeutics (NASDAQ:UTHR) Announces Quarterly Earnings Results, Beats Expectations By $0.23 EPS - MarketBeat
Earnings call: United Therapeutics reports robust Q3 growth, eyes future milestones - Investing.com
United Therapeutics: Q3 Earnings Snapshot - Milford Mirror
United Therapeutics Corp Q3 2024 Earnings: Revenue Hits $748.9M, EPS at $6.39, Surpassing Estimates - GuruFocus.com
United Therapeutics Corp (UTHR) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ... - Yahoo Finance
Decoding United Therapeutics Corp (UTHR): A Strategic SWOT Insig - GuruFocus.com
Decoding United Therapeutics Corp (UTHR): A Strategic SWOT Insight - Yahoo Finance
United Therapeutics Reports Strong Q3 2024 Results - TipRanks
Here's What Key Metrics Tell Us About United Therapeutics (UTHR) Q3 Earnings - Yahoo Finance
United Therapeutics (UTHR) Q3 Earnings and Revenues Top Estimates - Yahoo Finance
United Therapeutics earnings missed by $0.14, revenue topped estimates - Investing.com
United Therapeutics Corporation Reports Third Quarter 2024 Financial Results - StockTitan
Curious about United Therapeutics (UTHR) Q3 Performance? Explore Wall Street Estimates for Key Metrics - Yahoo Finance
China Universal Asset Management Co. Ltd. Has $3.07 Million Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
FCG Investment Co Acquires New Holdings in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
United Therapeutics (NASDAQ:UTHR) Trading Down 6.8% After Insider Selling - MarketBeat
United Therapeutics Corporation Announces the 500th Lung Transplant Utilizing its Centralized Ex Vivo Lung Perfusion Service - StockTitan
United Therapeutics Corporation to Report Third Quarter 2024 Financial Results Before the Market Opens on Wednesday, October 30, 2024 - StockTitan
United Therapeutics CFO sells shares worth $2.45 million By Investing.com - Investing.com Canada
United Therapeutics CFO sells shares worth $2.45 million - Investing.com
James Edgemond Sells 7,782 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock - MarketBeat
Toth Financial Advisory Corp Has $1.04 Million Stock Position in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
United Therapeutics (NASDAQ:UTHR) Upgraded to "Strong-Buy" by StockNews.com - MarketBeat
State Street Corp's Strategic Reduction in United Therapeutics Holdings - GuruFocus.com
United Therapeutics (NASDAQ:UTHR) Hits New 52-Week HighHere's What Happened - MarketBeat
United Therapeutics stock soars to all-time high of $366.23 - Investing.com
United Therapeutics stock soars to all-time high of $366.23 By Investing.com - Investing.com Australia
Livforsakringsbolaget Skandia Omsesidigt Sells 20,450 Shares of United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
United Therapeutics Co. (NASDAQ:UTHR) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
United Therapeutics CFO James Edgemond sells $2.37m in stock By Investing.com - Investing.com Australia
United Therapeutics CFO James Edgemond sells $2.37m in stock - Investing.com
United Therapeutics Co. (NASDAQ:UTHR) CFO Sells $2,773,016.96 in Stock - MarketBeat
Swedbank AB Decreases Stake in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
Inspire Investing LLC Reduces Holdings in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Diversified Trust Co - MarketBeat
United Therapeutics Co. (NASDAQ:UTHR) Short Interest Update - MarketBeat
United Therapeutics Corp (UTHR) Q2 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Focus - GuruFocus.com
United Therapeutics Corp Stock (UTHR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):